LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akciju saraksts・Anika Therapeutics Inc

Anika Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

14.85 -0.54

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.76

Max

14.88

Galvenie mērījumi
By Trading Economics
Ienākumi	-5.3M -5.1M
Pārdošana	-1M 30M
EPS	0.27
Peļņas marža	-17.074
Darbinieki	235
EBITDA	-6.3M -4.1M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+17.61% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-30M 199M
Iepriekšējā atvēršanas cena	15.39
Iepriekšējā slēgšanas cena	14.85

Ziņu noskaņojums

By Acuity

50%

159 / 345 Rangs Healthcare

Anika Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. maijs 08:24 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026. g. 25. maijs 21:22 UTC

Peļņas

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026. g. 25. maijs 20:50 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:20 UTC

Tirgus saruna

Peļņas

Basic Materials Roundup: Market Talk

2026. g. 25. maijs 16:01 UTC

Tirgus saruna

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026. g. 25. maijs 14:43 UTC

Tirgus saruna

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026. g. 25. maijs 14:15 UTC

Tirgus saruna

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026. g. 25. maijs 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 25. maijs 12:58 UTC

Tirgus saruna

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026. g. 25. maijs 12:56 UTC

Tirgus saruna

Peļņas

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026. g. 25. maijs 12:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 25. maijs 12:34 UTC

Tirgus saruna

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026. g. 25. maijs 12:10 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero's Assets Look Strategic -- Market Talk

2026. g. 25. maijs 11:00 UTC

Tirgus saruna

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026. g. 25. maijs 10:19 UTC

Tirgus saruna

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026. g. 25. maijs 10:05 UTC

Peļņas

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026. g. 25. maijs 10:04 UTC

Peļņas

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026. g. 25. maijs 10:03 UTC

Peļņas

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026. g. 25. maijs 10:02 UTC

Peļņas

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026. g. 25. maijs 10:01 UTC

Peļņas

Tenaga Nasional 1Q Net Up 3.7% on Year

2026. g. 25. maijs 10:00 UTC

Peļņas

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q EPS MYR0.1883

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Rev MYR17.1B

2026. g. 25. maijs 09:56 UTC

Peļņas

Tenaga Nasional 1Q Net MYR1.1B

2026. g. 25. maijs 09:38 UTC

Tirgus saruna

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 25. maijs 09:33 UTC

Tirgus saruna

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026. g. 25. maijs 08:55 UTC

Tirgus saruna

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Salīdzinājums

Cenas izmaiņa

Anika Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

17.61% augšup

Prognoze 12 mēnešiem

Vidējais 17.5 USD 17.61%

Augstākais 18 USD

Zemākais 17 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Anika Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Anika Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

159 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.